Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases

Barraclough, Katherine A.; Hawley, Carmel M.; McDonald, S.; Brown, Fiona G.; Rosman, Johan B.; Wiggins, Kathryn J.; Bannister, Kym M.; Johnson, David W.

doi:10.1093/ndt/gfp322

Cited by 43 publications

(45 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[163][164][165][166][167][168][169][170][171][172][173][174] After a single episode of peritonitis, the risks of death due to infection, cardiovascular disease, and dialysis withdrawal are markedly increased in the first month and continue to remain significantly elevated for up to 6 months afterward. 104,161,162 Depending on the underlying causative organism, PDrelated peritonitis is complicated by relapse in 3%-20% (14% overall), catheter removal in 10%-88% (22% overall), permanent HD transfer in 9%-74% (18% overall), and death in 0.9%-8.6% (2%-6% overall) of cases.…”

Section: Peritonitismentioning

confidence: 99%

The Current State of Peritoneal Dialysis

Mehrotra

Devuyst

Davies

et al. 2016

JASN

399

335

View full text Add to dashboard Cite

Technical innovations in peritoneal dialysis (PD), now used widely for the long-term treatment of ESRD, have significantly reduced therapy-related complications, allowing patients to be maintained on PD for longer periods. Indeed, the survival rate for patients treated with PD is now equivalent to that with in-center hemodialysis. In parallel, changes in public policy have spurred an unprecedented expansion in the use of PD in many parts of the world. Meanwhile, our improved understanding of the molecular mechanisms involved in solute and water transport across the peritoneum and of the pathobiology of structural and functional changes in the peritoneum with long-term PD has provided new targets for improving efficiency and for intervention. As with hemodialysis, almost half of all deaths on PD occur because of cardiovascular events, and there is great interest in identifying modality-specific factors contributing to these events. Notably, tremendous progress has been made in developing interventions that substantially reduce the risk of PD-related peritonitis. Yet the gains have been unequal among individual centers, primarily because of unequal clinical application of knowledge gained from research. The work to date has further highlighted the areas in need of innovation as we continue to strive to improve the health and outcomes of patients treated with PD.

show abstract

Section: Peritonitismentioning

confidence: 99%

The Current State of Peritoneal Dialysis

Mehrotra

Devuyst

Davies

et al. 2016

JASN

399

335

View full text Add to dashboard Cite

show abstract

“…Recent analyses of the Australian Peritonitis Registry also indicate that peritonitis outcomes are generally inferior to those reported in other regions of the world 29–35 . In Australia, cure rates with antibiotics alone range between 9% and 87%, depending on the particular microorganism(s) recovered, with an overall average cure rate of only 68% 29–35 .…”

Section: Introductionmentioning

confidence: 99%

Peritoneal dialysis practice in Australia and New Zealand: A call to action

et al. 2010

View full text Add to dashboard Cite

Peritoneal dialysis technique survival in Australia and New Zealand is lower than in other parts of the world. More than two-thirds of technique failures are related to infective complications (predominantly peritonitis) and 'social reasons'. Practice patterns vary widely and more than one-third of peritoneal dialysis units do not meet the International Society of Peritoneal Dialysis minimum accepted peritonitis rate. In many cases, poor peritonitis outcomes reflect significant deviations from international guidelines. In this paper we propose a series of practical recommendations to improve outcomes in peritoneal dialysis patients through appropriate patient selection, prophylaxis and treatment of infectious complications, investigation of social causes of technique failure and a greater focus on patient education and clinical governance.

show abstract

“…Szeto et al [19] recommend that vancomycin be used intraperitoneally as a first-line agent, with long-term use ([3 weeks) being associated with improved outcomes. In 2009, Barraclough et al [20], according to an analysis of 82 episodes of peritonitis in Australian adult patients, reported that Corynebacterium species are a pathogen in peritonitis (2.3% of all peritonitis episodes). The species breakdown was not analyzed.…”

Section: Discussionmentioning

confidence: 99%

Acute peritonitis due to Corynebacterium ulcerans in a patient receiving continuous ambulatory peritoneal dialysis: a case report and literature review

et al. 2010

View full text Add to dashboard Cite

A 55-year-old Japanese woman receiving continuous ambulatory peritoneal dialysis (CAPD) was admitted to our service with abdominal pain and cloudy peritoneal fluid. Laboratory data revealed a white blood cell count of 7.20 × 10(9 )cells/L, hemoglobin 9.8 g/dl, hematocrit 29.0%, platelet count 284 × 10(9 )cells/L, and C-reactive protein (CRP) 0.109 g/L. Peritoneal fluid white blood cell count of 2,000 cells/µl suggested acute peritonitis. An empiric trial of cefazolin and ceftazidime, subsequently switched to meropenem, vancomycin, minocycline, and amikacin, did not improve the patient's symptoms. The peritoneal fluid collected before initiation of antibiotic therapy grew Corynebacterium ulcerans. Ampicillin/sulbactam was started based on the culture and sensitivity data. On hospital day 8, the CAPD catheter was removed due to no clinical improvement and persistently increased levels of CRP to 0.0174 g/L. A 14-day course of ampicillin/sulbactam improved her clinical condition and laboratory data. Microbiological analysis revealed that C. ulcerans isolated from this patient did not produce diphtheria toxin. C. ulcerans was not isolated from her dog's oral and nasal cavities during a search for the route of her infection. We recommend that in patients with peritoneal dialysis, special attention should be paid to Corynebacterium peritonitis, especially due to C. ulcerans, which may produce diphtheria toxin, be resistant to multiple antibiotics, and frequently become recurrent.

show abstract

Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases

Cited by 43 publications

References 16 publications

The Current State of Peritoneal Dialysis

The Current State of Peritoneal Dialysis

Peritoneal dialysis practice in Australia and New Zealand: A call to action

Acute peritonitis due to Corynebacterium ulcerans in a patient receiving continuous ambulatory peritoneal dialysis: a case report and literature review

Contact Info

Product

Resources

About